M. Mateo Paz Soldán

M. Mateo Paz Soldán, MD, PhD

Languages spoken: English

Academic Information

Departments Adjunct - Neurology

Board Certification

  • American Board of Psychiatry & Neurology (Neurology)

Dr. Paz Soldán is assistant professor in the Neuroimmunology Division of Neurology at the University of Utah. His clinical interests focus on multiple sclerosis (MS), neuromyelitis optica (NMO), and other inflammatory or demyelinating diseases of the central nervous system. His interests extend to autoimmune neurologic diseases—those primarily affecting the nervous system, those occurring with rheumatologic disease, and those occurring in the setting of cancer (paraneoplastic). He also has interest in general clinical neurology.

Education History

Fellowship Mayo School of Graduate Medical Education
 Fellow
Mayo School of Graduate Medical Education
 Resident
Internship Mayo School of Graduate Medical Education
 Intern
Mayo Medical School
 MD
Postdoctoral Fellowship Sun Health Research Institute
 Postdoctoral Fellow
Mayo Graduate School
 PhD
Graduate Training Arizona State University
 MS
Arizona State University
 BS

Selected Publications

Journal Article

  1. Mustafa R, Flanagan EP, Duffy DJ, Weinshenker BG, Soldn MMP, Kunchok A, Kaisey M, Solomon AJ (2023). Laboratory evaluation for the differential diagnosis of possible multiple sclerosis in the United States: A physician survey. J Neurol Sci, 453, 120781. (Read full article)
  2. Spain RI, Hildebrand A, Waslo CS, Rooney WD, Emmons J, Schwartz DL, Freedman MS, Paz Soldan MM, Repovic P, Solomon AJ, Rinker J 2nd, Wallin M, Haselkorn JK, Stuve O, Gross RH, Turner AP (2023). Processing speed and memory test performance are associated with different brain region volumes in Veterans and others with progressive multiple sclerosis. Front Neurol, 14, 1188124. (Read full article)
  3. Poon JT, Salzman K, Clardy SL, Paz Soldan MM (2022). Adrenal Crisis Presenting as Recurrent Encephalopathy Mimicking Autoimmune, Infectious Encephalitis, and Common Variable Immune Deficiency: A Case Report. Neurologist, 27(4), 206-210. (Read full article)
  4. Williams JP, Abbatemarco JR, Galli JJ, Rodenbeck SJ, Peterson LK, Haven TR, Street M, Rose JW, Greenlee JE, Soldan MMP, Clardy SL (2021). Aquaporin-4 Autoantibody Detection by ELISA: A Retrospective Characterization of a Commonly Used Assay. Mult Scler Int, 2021, 8692328. (Read full article)
  5. Abbatemarco JR, Galli JR, Sweeney ML, Carlson NG, Samara VC, Davis H, Rodenbeck S, Wong KH, Paz Soldan MM, Greenlee JE, Rose JW, Delic A, Clardy SL (2021). Modern Look at Transverse Myelitis and Inflammatory Myelopathy: Epidemiology of the National Veterans Health Administration Population. Neurol Neuroimmunol Neuroinflamm, 8(6). (Read full article)
  6. Kassa RM, Sechi E, Flanagan EP, Kaufmann TJ, Kantarci OH, Weinshenker BG, Mandrekar J, Schmalstieg WF, Paz Soldan MM, Keegan BM (2020). Onset of progressive motor impairment in patients with critical central nervous system demyelinating lesions. Mult Scler, 27(6), 895-902. (Read full article)
  7. Hauser SL, Bar-Or A, Cohen JA, Comi G, Correale J, Coyle PK, Cross AH, de Seze J, Leppert D, Montalban X, Selmaj K, Wiendl H, Kerloeguen C, Willi R, Li B, Kakarieka A, Tomic D, Goodyear A, Pingili R, Hring DA, Ramanathan K, Merschhemke M, Kappos L, ASCLEPIOS I and ASCLEPIOS II Trial Groups (2020). Ofatumumab versus Teriflunomide in Multiple Sclerosis. N Engl J Med, 383(6), 546-557. (Read full article)
  8. Lord J, Paz Soldan MM, Galli J, Salzman KL, Kresser J, Bacharach R, DeWitt LD, Klein J, Rose J, Greenlee J, Clardy SL (2020). Neurosarcoidosis: Longitudinal experience in a single-center, academic healthcare system. Neurol Neuroimmunol Neuroinflamm, 7(4). (Read full article)
  9. Hollen CW, Paz Soldn MM, Rinker JR 2nd, Spain RI (2020). The Future of Progressive Multiple Sclerosis Therapies. Fed Pract, 37(Suppl 1), S43-S49. (Read full article)
  10. Piquet AL, Khan M, Warner JEA, Wicklund MP, Bennett JL, Leehey MA, Seeberger L, Schreiner TL, Paz Soldan MM, Clardy SL (2019). Novel clinical features of glycine receptor antibody syndrome: A series of 17 cases. Neurol Neuroimmunol Neuroinflamm, 6(5), e592. (Read full article)
  11. Toledano M, Weinshenker BG, Kaufmann TJ, Parisi JE, Paz Soldn MM (2018). Demographics and clinical characteristics of episodic hypothermia in multiple sclerosis. Mult Scler, 25(5), 709-714. (Read full article)
  12. Keegan BM, Kaufmann TJ, Weinshenker BG, Kantarci OH, Schmalstieg WF, Paz Soldan MM, Flanagan EP (2018). Progressive motor impairment from a critically located lesion in highly restricted CNS-demyelinating disease. Mult Scler, 24(11), 1445-1452. (Read full article)
  13. Galli JR, Clardy SL, Paz Soldn MM (2016). Adult-onset Opsoclonus-Myoclonus Syndrome Associated With Ganglionic Acetylcholine Receptor Autoantibody. Neurologist, 21(6), 99-100. (Read full article)
  14. Keegan BM, Kaufmann TJ, Weinshenker BG, Kantarci OH, Schmalstieg WF, Paz Soldan MM, Flanagan EP (2016). Progressive solitary sclerosis: Gradual motor impairment from a single CNS demyelinating lesion. Neurology, 87(16), 1713-1719. (Read full article)
  15. Novotna M, Paz Soldn MM, Abou Zeid N, Kale N, Tutuncu M, Crusan DJ, Atkinson EJ, Siva A, Keegan BM, Pirko I, Pittock SJ, Lucchinetti CF, Noseworthy JH, Weinshenker BG, Rodriguez M, Kantarci OH (2015). Poor early relapse recovery affects onset of progressive disease course in multiple sclerosis. Neurology, 85(8), 722-9. (Read full article)
  16. Paz Soldn MM, Raman MR, Gamez JD, Lohrey AK, Chen Y, Pirko I, Johnson AJ (2015). Correlation of Brain Atrophy, Disability, and Spinal Cord Atrophy in a Murine Model of Multiple Sclerosis. J Neuroimaging, 25(4), 595-9. (Read full article)
  17. Paz Soldn MM, Novotna M, Abou Zeid N, Kale N, Tutuncu M, Crusan DJ, Atkinson EJ, Siva A, Keegan BM, Pirko I, Pittock SJ, Lucchinetti CF, Weinshenker BG, Rodriguez M, Kantarci OH (2015). Relapses and disability accumulation in progressive multiple sclerosis. Neurology, 84(1), 81-8. (Read full article)
  18. Paz Soldn MM, Pittock SJ, Weigand SD, Yawn BP, Rodriguez M (2012). Statin therapy and multiple sclerosis disability in a population-based cohort. Mult Scler, 18(3), 358-63. (Read full article)
  19. Ciric B, Van Keulen V, Paz Soldan M, Rodriguez M, Pease LR (2004). Antibody-mediated remyelination operates through mechanism independent of immunomodulation. J Neuroimmunol, 146(1-2), 153-61. (Read full article)
  20. Ciric B, Howe CL, Paz Soldan M, Warrington AE, Bieber AJ, Van Keulen V, Rodriguez M, Pease LR (2003). Human monoclonal IgM antibody promotes CNS myelin repair independent of Fc function. Brain Pathol, 13(4), 608-16. (Read full article)
  21. Paz Soldn MM, Warrington AE, Bieber AJ, Ciric B, Van Keulen V, Pease LR, Rodriguez M (2003). Remyelination-promoting antibodies activate distinct Ca2+ influx pathways in astrocytes and oligodendrocytes: relationship to the mechanism of myelin repair. Mol Cell Neurosci, 22(1), 14-24. (Read full article)
  22. Mitsunaga Y, Ciric B, Van Keulen V, Warrington AE, Paz Soldan M, Bieber AJ, Rodriguez M, Pease LR (2002). Direct evidence that a human antibody derived from patient serum can promote myelin repair in a mouse model of chronic-progressive demyelinating disease. FASEB J, 16(10), 1325-7. (Read full article)
  23. Warrington AE, Bieber AJ, Ciric B, Van Keulen V, Pease LR, Mitsunaga Y, Paz Soldan MM, Rodriguez M (2001). Immunoglobulin-mediated CNS repair. J Allergy Clin Immunol, 108(4 Suppl), S121-5. (Read full article)

Review

  1. Paz Soldan MM, Pirko I (2012). Biogenesis and significance of central nervous system myelin. [Review]. Semin Neurol, 32(1), 9-14. (Read full article)
  2. Paz Soldan MM, Rodriguez M (2002). Heterogeneity of pathogenesis in multiple sclerosis: implications for promotion of remyelination. [Review]. J Infect Dis, 186 Suppl 2, S248-53. (Read full article)

Book Chapter

  1. Baldassari LE, Paz Soldan MM (2021). Natural History of Multiple Sclerosis. In Piquet AL, Alvarez E (Eds.), Neuroimmunology: Multiple Sclerosis, Autoimmune Neurology and Related Diseases (1st, pp. 535 pages). Switzerland: Springer International Publishing.

Editorial

  1. Paz Soldn MM, Weinshenker BG (2015). Moving targets for hematopoietic stem cell transplantation for multiple sclerosis. JAMA Neurol, 72(2), 147-9. (Read full article)

Abstract

  1. Wong K, Sorenson A, Hwang H, Noroozi S, Francis T, Germaine S, Wright M, Galli J, Kadish R, Klein J, Paz Soldan MM, Greenlee J, Rose JW, Smith T, Clardy SL (2023). Misdiagnosis of Neuromyelitis Optica Spectrum Disorder as Multiple Sclerosis: Multi-institutional database analysis in the United States [Abstract]. 29(3 suppl), P413.
  2. Kim SE, Francis T, Wong KH, Rose JW, McNally JS, Paz Soldan MM (2023). Novel MRI techniques for the Assessment of Activated Innate Immunity in Progressive Multiple Sclerosis [Abstract]. ePoster 3533.
  3. Liu S, Wright M, Wong K, Mizenko C, Kammeyer R, Schreiner T, Kadish R, Smith T, Galli J, Klein J, Greenlee JE, Rose JW, Paz Soldan MM, Bennett J, Bonkowsky J, Peterson L, Piquet A, Clardy SL (2022). MOGAD in the Mountain West: Epidemiology and Outcomes in Pediatric and Adult Patients at Two Large Academic Referral Centers [Abstract]. 98(18 Supplement), P16.003.
  4. Wong K, Bacharach R, Fjeldstad A, Klein J, Paz Soldan MM, Rose JW (2022). Longitudinal Assessment of Optical Coherence Tomography in Patients with Relapsing-Remitting Multiple Sclerosis on Interferon beta-1a [Abstract]. 98(18 Supplement), P15.009.
  5. Rodenbeck S, Abbatemarco J, Poon J, Liu S, Paz Soldan MM, Greenlee JE, Rose JW, Peterson L, Johnson L, Clardy SL (2022). Matched or Unique Cerebrospinal Fluid Oligoclonal Bands: Clinical Characteristics and Diagnostic Utility [Abstract]. 98(18 Supplement), S3.009.
  6. Lord J, Rose JW, Paz Soldan MM (2022). Autologous HSCT Outside of Clinical Trials in Patients with Multiple Sclerosis [Abstract]. 98(18 Supplement), P6.009.
  7. Hoshina Y, Galli J, Wong K, Kovacsovics T, Steinbach M, Lancaster E, Paz Soldan MM, Clardy SL (2022). Anti-GABAA receptor encephalitis in patients with multiple myeloma after autologous stem cell transplant: A report of 3 cases [Abstract]. 98(18 Supplement), P1.001.
  8. Waslo CS, Paz Soldan MM, Freedman MS, Repovic P, Solomon AJ, Rinker JR, Wallin MT, Haselkorn JK, Spain RI (2020). Challenges and Opportunities in Progressive Multiple Sclerosis Trials: Lessons from Lipoic Acid [Abstract]. 22(s2), 10-11.
  9. Esquibel L, De Almeida B, Millsap L, Galli J, Gundlapalli A, Paz Soldan MM, Klein J, Cortez M, Rose J, Greenlee J, Hill H, Wong K, Clardy SL (2020). Evaluation of the Prevalence of Headache and Pain of Unknown Cause in Patients with Common Variable Immunodeficiency (CVID) [Abstract]. 94(15 Suppl.), 794.
  10. Kadish R, Wong K, Galli J, Greenlee J, Klein J, Paz Soldan MM, Clardy S, Rose J (2020). Characterization of Retinal Nerve Fiber Layer Thickness in a Cohort with Anti-Glutamic Acid Decarboxylase and Anti-Glycine Receptor Autoimmunity [Abstract]. 94(15 Suppl.), 2227.
  11. Kassa RM, Sechi E, Flanagan EP, Kaufmann TJ, Kantarci OH, Weinshenker BG, Mandrekar J, Schmalstieg WF, Paz Soldan MM, Keegan BM (2020). Onset of Progressive Motor Impairment in Patients with Critical CNS Demyelinating Lesions [Abstract]. 94(15 Suppl.), 4405.
  12. De Almeida BI, Esquibel L, Millsap L, Klein J, Galli J, Cortez MM, Paz Soldan MM, Gundlapalli A, Greenlee J, Rose J, Hill H, Wong K, Clardy S (2020). Cognitive and Depressive Symptoms in Adults with Common Variable Immunodeficiency (CVID) [Abstract]. 94(15 Suppl.), 4502.
  13. Steiner S, Durman G, Paz Soldan MM, Woltz S, Wong K, Rose J (2020). Neurogenic Pain in Multiple Sclerosis: A Single Center Comprehensive Pain Assessment [Abstract]. 94(15 Suppl.), 4592.
  14. Wong K, Bacharach R, Klein J, Paz Soldan MM, Rose J (2020). Longitudinal Assessment of Optical Coherence Tomography in Patients with Relapsing-Remitting Multiple Sclerosis on Three Disease Modifying Therapies. Neurology [Abstract]. 94(15 Suppl.), 4691.
  15. De Almeida BI, Wong K, Millsap L, Cortez M, Greenlee JE, Gundlapalli A, Hill H, Paz Soldan MM, Rose J, Galli J, Clardy SL (2019). Neurological Manifestations in Common Variable Immunodeficiency [Abstract]. 86(Suppl. 24), S36 (S108).
  16. Kassa RM, Sechi E, Flanagan EP, Weinshenker BG, Kantarci OH, Kaufmann TJ, Schmalstieg WF, Paz Soldan MM, Keegan BM (2019). Age of onset of progressive motor impairment in patients with critical demyelinating lesions [Abstract]. 25(Suppl. 2), 673 (P1243).
  17. Klonoski J, Palmer C, Clardy S, Paz Soldan MM, Lancaster E, Peterson L (2019). Histopathologic presentation of two cases of GABAa-R autoimmune encephalitis [Abstract]. 78(6), 575 (P218).
  18. Wong K, Bacharach R, Marini E, Nguyen T, Clardy S, Cortez M, DeWitt LD, Greenlee J, Klein J, Paz Soldan MM, Steffens J, Rose J (2019). Dimethyl Fumarate Dose Reduction in Lymphopenic Relapsing Remitting Multiple Sclerosis Patients: Clinical and MRI Outcomes [Abstract]. 92(15 Suppl.), P4.2-013.
  19. Galli J, Piquet A, Kresser J, Klein J, Warner J, Digre K, Peterson L, Tebo A, Haven T, Paz Soldan MM, Rose J, Greenlee J, Clardy S (2019). GAD65 and Glycine Receptor-Associated Neurologic Autoimmunity and Stiff-Person Syndrome within the University of Utah Health Care System [Abstract]. 92(15 Suppl.), P2.2-036.
  20. Lord J, Bacharach R, Galli J, Kresser J, Klein J, DeWitt LD, Paz Soldan MM, Rose J, Greenlee J, Clardy S (2019). Neurosarcoidosis: Longitudinal Experience in a Single-Center, Academic Health Care System [Abstract]. 92(15 Suppl.), P1.2-046.
  21. Piquet AL, Khan M, Warner JEA, Wicklund MP, Leehey MA, Schreiner T, Paz Soldan MM, Clardy SL (2018). Clinical Features of Glycine Receptor Antibody Syndrome: A Series of Eleven Cases [Abstract]. Annals of Neurology, 84(Suppl. 22), S1.
  22. Waheed MO, Wong K, Clardy SL, Cortez MM, Dewitt LD, Klein JM, Paz Soldan MM, Steffens JD, Rose JW (2018). Transition from Natalizumab to Dimethyl Fumarate in Multiple Sclerosis Patients: Clinical and Magnetic Resonance Imaging Outcomes [Abstract]. International Journal of MS Care, 20(Suppl. 1), 29-30.
  23. Wong K, Marini E, Nguyen TP, Clardy SL, Cortez MM, DeWitt LD, Greenlee JE, Klein JM, Paz Soldan MM, Steffens JD, Rose JW (2018). Dimethyl Fumarate in Relapsing Remitting Multiple Sclerosis: 24 Months Observations of the Effects of Dose Reduction on Lymphopenia [Abstract]. Neurology, 90(15 Suppl.), P6.347.
  24. Williams JP, Street M, Badger JK, Peterson LK, Greenlee JE, Carlson NG, Rose JW, Paz Soldan MM, Clardy SL (2018). Characterization and Alternative Diagnoses in Patients with False-positive Aquaporin-4 Autoantibody Detection by Enzyme-Linked Immunosorbent Assay (ELISA) [Abstract]. Neurology, 90(15 Suppl.), P6.420.
  25. Williams JP, Galli JR, Groshans KA, Horvat DE, Austin S, Pittock SJ, Rose JW, Carlson NG, Greenlee JE, Paz Soldan MM, Tagg NT, Clardy SL (2018). Neuromyelitis Optica Spectrum Disorder (NMOSD) in Active Duty Service Members [Abstract]. Neurology, 90(15 Suppl.), P6.424.
  26. Keegan BM, Kaufmann TJ, Weinshenker BG, Kantarci OH, Schmalstieg WF, Paz Soldan MM, Flanagan EP (2018). Progressive Motor Impairment from a Critically Located Lesion in Highly Restricted CNS Demyelinating Disease [Abstract]. Neurology, 90(15 Suppl.), P5.034.
  27. Keegan BM, Kaufmann TJ, Weinshenker BG, Kantarci OH, Schmalstieg WF, Paz Soldan MM, Flanagan EP (2017). Motor progression from a single critically located demyelinating lesion in paucisclerotic MS [Abstract]. Multiple Sclerosis Journal, 23(Suppl. 3), 437.
  28. Carlson NG, Schmidt LA, Wood B, Clendennon C, Weber LM, Paz Soldan MM, Rose JW (2017). Remyelination following oral administration of dimethyl fumarate in the Theiler’s murine encephalomyelitis virus model of multiple sclerosis [Abstract]. Multiple Sclerosis Journal, 23(Suppl. 3), 622.
  29. Baldassari LE, Seraj H, Husebye CD, Paz Soldn MM, Martins TB, Carlson NG, Rose JW (2017). Cytokine Profiles Across DR2 Haplotype and Vitamin D Status in the Intermountain Multiple Sclerosis Project [Abstract]. 2017 Annual Meeting of the Consortium of Multiple Sclerosis Centers, ND03.
  30. Piquet AL, Baldassari LE, Paz Soldn MM (2017). Highly active relapsing remitting multiple sclerosis following hematopoietic stem cell transplantation: a case report [Abstract]. Neurology, 88(16 Suppl.), P6.355.
  31. Wong K, Marini E, Clardy SL, DeWitt LD, Klein JM, Paz Soldan MM, Rose JW (2017). Dimethyl Fumarate in Relapsing Remitting Multiple Sclerosis: Effects of Dose Reduction on Lymphopenia [Abstract]. Neurology, 88(16 Suppl.), P5.373.
  32. Baldassari LE, Seraj H, Husebye CD, Paz Soldn MM, Martins TB, Carlson NG, Rose JW (2017). Baseline characteristics and cytokine profiles across demographic subsets in the Intermountain Multiple Sclerosis Project [Abstract]. Neurology, 88(16 Suppl.), P1.382.
  33. Samara VC, Sweeney M, Carlson H, Paz Soldan MM, Greenlee JE, Carlson NG, Rose JW, Clardy SL (2016). Transverse Myelitis in Veterans [Abstract]. Annals of Neurology, 80(Suppl. 20), S203.
  34. Conway BL, Zeydan B, Novotna M, Paz Soldan MM, Tutuncu M, Siva A, Rodriguez M, Kantarci OH (2016). Amount and time to maximal recovery from multiple sclerosis relapses declines with age [Abstract]. Multiple Sclerosis Journal, 22(Suppl. 3), 111.
  35. Carlson NG, Schmidt LA, Wood B, Clendennen C, Weber LM, Paz Soldan MM, Rose JW (2016). Therapeutic effects of oral dimethyl fumarate in the Thiler's murine encephalomyelitis virus model of multiple sclerosis [Abstract]. Multiple Sclerosis Journal, 22(Suppl. 3), 163.
  36. Carlson H, Haringer V, Sweeney M, Rose JW, Carlson NG, Greenlee JE, Paz Soldan MM, Clardy SL (2016). Transverse Myelitis in Veterans: Epidemiology and Outcomes [Abstract]. Neurology, 86(16 Suppl.), P6.129.
  37. Sweeney ML, Paz Soldan MM, Lowichik A, Sweney MT, Clardy SL (2016). A Pediatric Patient with ANNA-1 Associated Opsoclonus Myoclonus and Epilepsia Partialis Continua [Abstract]. Neurology, 86(16 Suppl.), P5.137.
  38. Galli J, Greenlee JE, Paz Soldan MM, Clardy SL (2016). Epidemiology of Stiff Person Syndrome in the United States Veterans Health Administration Database [Abstract]. Neurology, 86(16 Suppl.), P3.356.
  39. Keegan BM, Kaufmann TJ, Weinshenker BG, Kantarci OH, Schmalstieg WF, Paz Soldan MM, Flanagan EP (2016). Progressive Solitary Sclerosis: Insidious Motor Impairment Localized to an Isolated CNS Demyelinating Lesion [Abstract]. Neurology, 86(16 Suppl.), P3.008.
  40. Novotna M, Conway B, Zeydan B, Paz Soldan MM, Abou Zeid N, Kale N, Tutuncu M, Kantarci OH (2016). Predicting the End of Symptomatic Relapses and Disease Modifying Treatment Use Decisions in Progressive Multiple Sclerosis [Abstract]. Neurology, 86(16 Suppl.), S24.001.
  41. Carlson NG, Schmidt L, Redd J, Bellamkonda S, Wood B, Weber LM, Paz Soldn MM, Rose JW (2015). Vulnerability of oligodendrocyte precursor cells to death is modulated by key prostaglandins [Abstract]. Multiple Sclerosis Journal, 21(Suppl. 11), 467-468.
  42. Novotna M, Paz Soldn MM, Abou Zeid N, Kale N, Tutuncu M, Kantarci OH (2015). Defining the overlapping period of relapsing-remitting and progressive phases of multiple sclerosis for continuing disease modifying treatments [Abstract]. Multiple Sclerosis Journal, 21(Suppl. 11), 91-92.
  43. Toledano M, Weinshenker BG, Paz Soldn MM (2015). Demographics and characteristics of multiple sclerosis-related hypothermia [Abstract]. Multiple Sclerosis Journal, 21(Suppl. 11), 729-730.
  44. Galli JR, Clardy SL, Paz Soldn MM (2015). Ganglionic acetylcholine receptor autoantibody-associated opsoclonus-myoclonus syndrome [Abstract]. Annals of Neurology, 78(Suppl. 19), S75.
  45. Paz Soldn MM, Schmidt LA, Wood BL, Rose JW, Carlson NG (2015). Prostaglandin F2α Receptor Mediates Oligodendrocyte Precursor Injury/Death: Potential Role in Multiple Sclerosis [Abstract]. Neurology, 84(14 Suppl.), P5.210.
  46. Paz Soldan MM, Flanagan EP, Kantarci OH (2014). Highly active multiple sclerosis and Epstein-Barr virus reactivation [Abstract]. Mult Scler, 20(Suppl. 1), 229-230.
  47. Paz Soldan MM, Gamez JD, Raman M, Macura SI, Johnson AJ, Pirko I (2014). MRI measured brain and spinal cord atrophy differ between mouse strains in a murine model of MS [Abstract]. ISMRM 2014; Abstract No. 3382.
  48. Novotna M, Tutuncu M, Paz Soldan MM, Crusan DJ, Atkinson EJ, Kantarci OH (2014). Early relapse-recovery impacts progressive disease course in multiple sclerosis [Abstract]. Neurology, 82(10 Suppl.), S34.006.
  49. Paz Soldan MM, Martina N, Crusan DJ, Atkinson EJ, Kantarci OH (2013). Pre- and post-progression relapses impact disability in progressive multiple sclerosis [Abstract]. Mult Scler, 19(Suppl. 1), 65.
  50. Paz Soldan MM, Tutuncu M, Tang J, Abou Zeid N, Kale N, Crusan DJ, Atkinson EJ, Siva A, Pittock SJ, Pirko I, Keegan BM, Lucchinetti CF, Noseworthy JH, Rodriguez M, Weinshenker BG, Kantarci OH (2013). Predicting tempo of post-progression disability accumulation in multiple sclerosis [Abstract]. Neurology, 80(7 Suppl.), P02.147.
  51. Paz Soldan MM, Gamez JD, Johnson AJ, Lohrey AK, Chen Y, Pirko I (2011). Correlation of brain atrophy, disability and spinal cord atrophy in a murine model of MS [Abstract]. Annals of Neurology, 70(Suppl. 15), S70 (T1715).
  52. Paz Soldn MM, Rodriguez M (1999). Remyelination promoting antibodies mediate Ca2+ responses in oligodendrocytes [Abstract]. Society for Neuroscience Southern Minnesota Chapter Poster Session, Rochester, MN.